224 related articles for article (PubMed ID: 24732155)
1. Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging.
Maurer AH; Elsinga P; Fanti S; Nguyen B; Oyen WJ; Weber WA
J Nucl Med; 2014 May; 55(5):701-4. PubMed ID: 24732155
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide).
Morris RT; Joyrich RN; Naumann RW; Shah NP; Maurer AH; Strauss HW; Uszler JM; Symanowski JT; Ellis PR; Harb WA
Ann Oncol; 2014 Apr; 25(4):852-858. PubMed ID: 24667717
[TBL] [Abstract][Full Text] [Related]
3. The folate receptor as a rational therapeutic target for personalized cancer treatment.
Assaraf YG; Leamon CP; Reddy JA
Drug Resist Updat; 2014; 17(4-6):89-95. PubMed ID: 25457975
[TBL] [Abstract][Full Text] [Related]
4. Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer.
Ambrosio AJ; Suzin D; Palmer EL; Penson RT
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):443-50. PubMed ID: 24742319
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and in vitro/in vivo evaluation of 99mTc-labeled folate conjugates for folate receptor imaging.
Lu J; Pang Y; Xie F; Guo H; Li Y; Yang Z; Wang X
Nucl Med Biol; 2011 May; 38(4):557-65. PubMed ID: 21531293
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial of 99mTc-etarfolatide, an imaging agent for folate receptor in healthy Japanese adults.
Yamada Y; Nakatani H; Yanaihara H; Omote M
Ann Nucl Med; 2015 Nov; 29(9):792-8. PubMed ID: 26238440
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo evaluation of (99m)Tc-DO3A-EA-Folate for receptor-mediated targeting of folate positive tumors.
Mishra G; Hazari PP; Kumar N; Mishra AK
J Drug Target; 2011 Nov; 19(9):761-9. PubMed ID: 21425922
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of isostructural Tc-99m- and Re-188-folate-Gly-Gly-Cys-Glu for folate receptor-positive tumor targeting.
Kim WH; Kim CG; Kim MH; Kim DW; Park CR; Park JY; Lee YS; Youn H; Kang KW; Jeong JM; Chung JK
Ann Nucl Med; 2016 Jun; 30(5):369-79. PubMed ID: 26993818
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Preclinical Evaluation of Folate-NOTA-Al(18)F for PET Imaging of Folate-Receptor-Positive Tumors.
Chen Q; Meng X; McQuade P; Rubins D; Lin SA; Zeng Z; Haley H; Miller P; González Trotter D; Low PS
Mol Pharm; 2016 May; 13(5):1520-7. PubMed ID: 27054811
[TBL] [Abstract][Full Text] [Related]
10. Clinical translation of folate receptor-targeted therapeutics.
Teng L; Xie J; Teng L; Lee RJ
Expert Opin Drug Deliv; 2012 Aug; 9(8):901-8. PubMed ID: 22663189
[TBL] [Abstract][Full Text] [Related]
11. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
Naumann RW; Coleman RL; Burger RA; Sausville EA; Kutarska E; Ghamande SA; Gabrail NY; Depasquale SE; Nowara E; Gilbert L; Gersh RH; Teneriello MG; Harb WA; Konstantinopoulos PA; Penson RT; Symanowski JT; Lovejoy CD; Leamon CP; Morgenstern DE; Messmann RA
J Clin Oncol; 2013 Dec; 31(35):4400-6. PubMed ID: 24127448
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of receptor-based tumor imaging agent: (99m)Tc-folate-glucaric acid.
Onursal M; Lambrecht FY; Ozgur A
Int J Pharm; 2011 Sep; 416(1):288-92. PubMed ID: 21782912
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of novel organometallic 99mTc-folate and 99mTc-pteroate radiotracers for folate receptor-positive tumour targeting.
Müller C; Hohn A; Schubiger PA; Schibli R
Eur J Nucl Med Mol Imaging; 2006 Sep; 33(9):1007-16. PubMed ID: 16763819
[TBL] [Abstract][Full Text] [Related]
14. Folate-PEG-NOTA-Al
Chen Q; Meng X; McQuade P; Rubins D; Lin SA; Zeng Z; Haley H; Miller P; González Trotter D; Low PS
Mol Pharm; 2017 Dec; 14(12):4353-4361. PubMed ID: 29028357
[TBL] [Abstract][Full Text] [Related]
15. Development of a New FR-Targeting Agent
Guo Z; You L; Shi C; Song M; Gao M; Xu D; Peng C; Zhuang R; Liu T; Su X; Du J; Zhang X
Mol Pharm; 2017 Nov; 14(11):3780-3788. PubMed ID: 28969422
[TBL] [Abstract][Full Text] [Related]
16. Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors.
Fisher RE; Siegel BA; Edell SL; Oyesiku NM; Morgenstern DE; Messmann RA; Amato RJ
J Nucl Med; 2008 Jun; 49(6):899-906. PubMed ID: 18483093
[TBL] [Abstract][Full Text] [Related]
17. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors.
Müller C; Schubiger PA; Schibli R
Nucl Med Biol; 2007 Aug; 34(6):595-601. PubMed ID: 17707798
[TBL] [Abstract][Full Text] [Related]
18. EC145: a novel targeted agent for adenocarcinoma of the lung.
Pribble P; Edelman MJ
Expert Opin Investig Drugs; 2012 May; 21(5):755-61. PubMed ID: 22462761
[TBL] [Abstract][Full Text] [Related]
19. Vintafolide: a novel targeted agent for epithelial ovarian cancer.
Graybill WS; Coleman RL
Future Oncol; 2014 Mar; 10(4):541-8. PubMed ID: 24754586
[TBL] [Abstract][Full Text] [Related]
20. In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.
Fani M; Tamma ML; Nicolas GP; Lasri E; Medina C; Raynal I; Port M; Weber WA; Maecke HR
Mol Pharm; 2012 May; 9(5):1136-45. PubMed ID: 22497506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
